Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News and Views
Nature Cell Biology 8, 785–786 (1 August 2006) | doi:10.1038/ncb0806-785
Eph tumour suppression: the dark side of Gleevec
Abstract
One of the most celebrated triumphs of basic cancer research in recent years has been the development of Gleevec for chronic myelogenous leukaemia (CML) therapy. The active ingredient in Gleevec (imatinib myselate, also known as STI571) inhibits the oncogenic BCR–ABL tyrosine kinase in CML cells.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
